Background {#Sec1}
==========

The neuronal ceroid lipofuscinoses (NCLs or CLNs), also called Batten disease, are a set of neurodegenerative genetic disorders with an overall frequency of 1 in 100,000 individuals around the world \[[@CR1], [@CR2]\]. This condition conforms to an autosomal recessive (AR) pattern of inheritance and is mainly caused by consanguineous marriage \[[@CR3]\]. Babies affected with these lysosomal storage diseases do not manifest any clinical symptoms at birth; however, signs and symptoms mostly begin before 7 years of age depending on the gene involved \[[@CR3], [@CR4]\]. These conditions are genetically heterogeneous and consist of a wide spectrum of phenotypical and clinical manifestations. NCLs are characterized by the accumulation of autofluorescent lipopigments in cells \[[@CR5]\] and one of the most important pathological manifestations is ceroid accumulation in lysosomes \[[@CR1], [@CR6]\]. The accumulation of storage material in nerve cells results in massive neuronal loss and subsequent apoptosis, as has been shown in an autopsy of the brain \[[@CR7]\]. The categorization of various types of NCLs is based on the phenotype and the genes that are mutated. Accumulatively, mutation in at least 15 different genes has been shown to be implicated in the pathogenesis of at least nine different types of NCLs which result in a similar pathological and clinical manifestation; Table [1](#Tab1){ref-type="table"} \[[@CR8]--[@CR10]\]. Genes involved in the pathogenesis of NCLs are mainly affected by loss-of-function mutations \[[@CR11], [@CR12]\].Table 1Different types of neuronal ceroid lipofuscinosisTypes of NCLsPatternOnsetGeneChromosome locationNCL1ARInfantile\
Adulthood (mild form)*PTT1*/*CLN1*1p32NCL2ARLate infantile*TPP1*/*CLN2*11p15.5NCL3Juvenile*CLN3*16p12.1NCL4AR\
ADAdulthood*CLN6*\
*DNAJC5*15q21-q23\
20q13.33NCL5ARLate infantile\
Adulthood (mild form)*CLN5*13q21.1-q32NCL6ARLate infantile*CLN6*15q21.q23NCL7ARLate infantile*CLN7*/*MFSD8*4q28.1-q28.2NCL8ARLate infantile*CLN8*8p23.3NCL9ARJuvenileUnknownUnknownNCL10ARNewborn\
Adulthood\
(mild form)*CLN10*/*CTSD*1p15.5*AD* autosomal dominant, *AR* autosomal recessive, *NCL* neuronal ceroid lipofuscinosis

Phenotypically, there are three common different forms of NCLs; the categorization of these three forms of NCLs is mainly based on the age of onset: infantile NCL (INCL) that begins between 6 and 18 months of age; late INCL (LINCL) which begins at 2--4 years of age; and juvenile NCL (JNCL) which begins at the age of 6--10 years or sometimes in adulthood \[[@CR13]--[@CR15]\]. All types show overlapping sign and symptoms, mainly cognitive impairment, progressive neuronal degeneration, motor deficits, seizures, progressive visual deterioration, and blindness \[[@CR16]\]. Motor dysfunction could lead to subsequent quadriplegia \[[@CR17], [@CR18]\]. The genes involved in NCLs present similar clinical manifestations; so, the finding of genetic mutations may explain unclear clinical findings and distinguish between them \[[@CR19], [@CR20]\].

The most prevalent types of NCLs are NCL1, which is considered an infantile form, NCL2, which is considered a late infantile form, and NCL3, which is considered a juvenile form \[[@CR21]\]. NCL1 is the most common form of INCLs. At birth, a baby with NCL1 has normal development, but this process is lost and motor dysfunction leads to hypotonia \[[@CR22]\]. There is evident vision loss and seizure at approximately 1 year of age \[[@CR23]\]. Profound microcephaly is a usual finding and patients will usually die before they reach the age of 7 years. Mutation in the palmitoyl-protein thioesterase (*PPT*) gene which encodes a fatty acid cleavage lysosomal protein is the cause of NCL1. R122W (c.364A\>T) and R151X (c.451C\>T) are the most common mutations of the *PTT* gene and accounted for approximately 20% of mutations \[[@CR2]\]. NCL2, also called Jansky--Bielschowsky disease, in which almost the majority of affected patients' manifestations begin at late infantile period of life, is caused by mutations in the *CLN2* gene which encodes tripeptidyl-peptidase 1 (TPP1) \[[@CR24]\]. NCL3 is the juvenile form of this disease and often diagnosed with retinitis pigmentosa and late onset seizures at the second decade of life \[[@CR25]\]. There are other various types of NCLs; some of these conform to an autosomal dominant pattern of inheritance (types of NCL4 which are caused by mutation in the *DNAJC5* gene). NCL10 is the most malignant form and the only type of NCL which affect newborns \[[@CR26]--[@CR28]\]. NCL7 is caused by mutations in the *MFSD8*/*CLN7* gene and is a LINCL type \[[@CR27], [@CR28]\].

Case presentation {#Sec2}
=================

A 5-year-old Iranian boy with a neurodegenerative disorder was referred for genetic testing. His clinical symptoms were speech problems, lack of concentration, walking disability at age of 4 years leading to quadriplegia, spontaneous laughing and crying because of hidden seizure, clumsiness, psychomotor delay, and vision deterioration at age of 5 years which could be the consequence of macular dystrophy. Brain magnetic resonance imaging (MRI) and electroencephalogram (EEG) showed bilateral white matter signal change with preservation of white matter (Fig. [1](#Fig1){ref-type="fig"} and Fig. [2](#Fig2){ref-type="fig"}). There are no available histopathological studies or skin biopsy for this patient.Fig. 1Brain magnetic resonance imaging of patientFig. 2Brain electroencephalogram of patient

The organic acids in his urine were determined using gas chromatography--mass spectrometry (GC-MS) of the trimethylsilyl ethers and esters of the ethyl acetate extract from acidified urine after preparation of the ethoxime derivatives. The organic acid in the urine of this patient showed a normal pattern with no evidence for metabolic disorders. There is no evidence for tyrosinemia, glutaric aciduria, methylmalonic aciduria, Canavan disease, propionic aciduria, isovaleric aciduria, and other organic aciduria known in Iran. Neonatal screening, clinical chemistry, and metabolism assays showed a normal pattern and these analyses were unremarkable (Table [2](#Tab2){ref-type="table"} and Table [3](#Tab3){ref-type="table"}).Table 2Neonatal screeningAssayResultReference rangeNeonatal screening Thyroid-stimulating hormone (TSH)\<  10 mU/l\<  10 mU/l 17-OH progesterone\<  5 nmol/l\<  5 nmol/l Galactose (GAL; GAL-1-P)\<  18 mg/dL\<  18 mg/dL Succinylacetone\<  5 μmol/l\<  5 μmol/l GAL-1-P uridyltransferase\>  20% activity\>  20% activity Biotinidase\>  30% activity\>  30% activityDisorder of amino acid metabolism Amino acids (including phenyl.) TMSDisorders of beta oxidation of fatty acids MCADDUnremarkable VLCADDUnremarkable LCHADDUnremarkableDisorders of carnitine metabolism Acylcarnitines. TMSUnremarkableDisorders of organic acids IsovalerylcarnitineUnremarkable Glutaric acidUnremarkableDefects of urea cycle CitrullineUnremarkable ArgininosuccinateUnremarkable*act*, *Gal-1-P* galactose-1-phosphate, *LCHADD* long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, *MCADD* medium-chain acyl-CoA dehydrogenase deficiency, *phenyl* phenylalanine, *TMS* tandem mass spectrometry, *VLCADD* very long-chain acyl-CoA dehydrogenase deficiencyTable 3Clinical chemistry and metabolism assaysAssayResultReference rangeCreatinine0.89 g/l0.12--1.12 g/lDocosanoic acid (C22)45.8 nmol/ml15--113 nmol/mlTetracosanoic acid (C24)41.6 nmol/ml12--94 nmol/mlHexacosanoic acid (C26)0.4 nmol/ml0.2--1.6 nmol/mlC24/C220.910.55--1.05C26/C220.0090.005--0.029Phytanic acid3.2 nmol/ml0.3--31 nmol/mlAryl sulfatase A0.808 mu/mg0.375--1.815Aryl sulfatase B1.654 mu/mg0.722--3.749

Our patient's parents are first cousins and had experienced three gestations, the first one aborted spontaneously before 4 weeks of pregnancy. The second one is the male reported here and the third one is a 2-year-old girl who does not manifest any signs and symptoms yet and seems to be normal. The pedigree is shown in Fig. [3](#Fig3){ref-type="fig"}.Fig. 3Pedigree of family affected by neuronal ceroid lipofuscinosis. *\# de novo* or inherited deletion, *+ heterozygous* inferred from pedigree, *\* heterozygous* confirmed by deletion analysis or Sanger sequencing. The *arrow* shows the proband in the family

Deoxyribonucleic acid (DNA) was extracted from peripheral blood of our patient and his healthy parents. Whole exome sequencing (WES) was performed on all three samples as following. Approximately 37 mega base pairs (Mb; 214,405 exons) of the Consensus Coding Sequences (CCS) were enriched from fragmented genomic DNA by \> 340,000 probes designed against the human genome (Nextera Rapid Capture Exome, Illumina) and the generated library sequenced on an Illumina HiSeq 4000 platform (Illumina) to an average coverage depth of more than 100 × (Table [4](#Tab4){ref-type="table"}). An end-to-end bioinformatics pipeline including base calling, primary filtering of low quality reads and probable artifacts, and annotation of variants was applied. All disease-causing variants reported in HGMD® or ClinVar (class 1) as well as all variants with minor allele frequency (MAF) of less than 1% in Exome Aggregation Consortium (ExAC) database were considered. The evaluation focused on exons and intron boundaries +/− 20. All relevant inheritance patterns were considered and clinical information was used to evaluate eventually identified variants. Relevant variants identified by WES were validated by Sanger sequencing in forward and reverse direction. By applying different filtering steps mentioned in the method part we ended up with only two novel variants in *MFSD8* and *AFF2* genes (Table [5](#Tab5){ref-type="table"}).Table 4Analysis statistics, average coverage and % target base pairs covered% target bp coveredAverage coverage (X)0X≥ 1X≥ 5X≥ 10X≥ 20X≥ 50XIndex111.690.1799.8399.3498.5796.5185.37Mother101.420.3399.6798.9597.9895.3682.09Father106.150.1999.8199.2598.3295.8683.15*bp* base pairsTable 5Results of trio whole exome sequencing and significant findingsGene (transcript)Nucleotide (protein)ZygosityDescribed by*In silico* parameters\*MAF\*\*Variant classification\*\*\*Disorder (OMIM\# inheritance)IndexMotherFather*AFF2*\
(NM_002025.3)c.259A\>G\
(p.Asn87Asp)Hem.Het.--Not described2/4 DamagingNot\
detectedSignificance uncertain (class 3)*AFF2*-related X-linked mental retardation (309,548, XLR)*MFSD8*\
(NM_152778.2)c.325_339del (p.Val109_Ile113del)Hom.Het.Het.Not describedIn-frame small deletionNot\
detectedSignificance uncertain (class 3)Neuronal ceroid lipofuscinosis type 7(610,951, AR)\* number of *in silico* prediction programs that predict pathogenicity/all applicable programs (SIFT, PolyPhen-2, AlignGVD, MutationTaster), \*\* highest minor allele frequency (MAF) of representative population -- Exome Aggregation Consortium (ExAC) database, Exome Sequencing Project (ESP), or 1000 Genomes Project (1000G), \*\*\* based on ACMG recommendations, *ACMG* American College of Medical Genetics and Genomics, *AR* autosomal recessive, *hem* hemizygous, *het* heterozygous, *hom* homozygous, *MAF* minor allele frequency, *OMIM* Online Mendelian Inheritance in Man, *XLR* X-Linked Recessive

The c.325_339del (p.Val109_Ile113del) variant in the *MFSD8* gene was a previously unreported variant and found to be homozygous in our patient whereas his parents were heterozygote carriers (Table [5](#Tab5){ref-type="table"}). Segregation analysis of this variant was done in the affected index, his parents, and relatives. It is a deletion of 15 base pairs (bp), which causes the loss of five residues. The evolutionary conservation of amino acid residues in the region of deletion estimated by ConSurf tool \[[@CR29]\] is shown in Fig. [4](#Fig4){ref-type="fig"}.Fig. 4The conservation scale adapted from the ConSurf Service. <http://consurf.tau.ac.il/2016/>. Mutated domain highlighted in *box*

The c.259A\>G (p.Asn87Asp) variant found in *AFF2* was a hemizygous change in our patient; his mother was also heterozygous whereas his father was negative for this variant. This variant had not been reported in the public databases at the time of this publication (Table [5](#Tab5){ref-type="table"}).

Discussion {#Sec3}
==========

The identified variant is a 15 bp in-frame deletion in *MFSD8* gene. Pathogenic variants in the *MFSD8* gene have been shown to be associated with AR NCL type 7. Visual loss and seizures may be the initial signs and symptoms. Epilepsy, ataxia, and myoclonus may be the initial features \[[@CR28]\] in children with age of onset after 4 years (Tables [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"}). Segregation analysis in this family found 15 bp in-frame deletion in *MFSD8* gene which is compatible with disease (Fig. [3](#Fig3){ref-type="fig"}).Table 6*AFF2* and *MFSD8* genes information and aliasesGeneEnsembl/OMIM ID/Gene Ontology/AliasesLocation/Exon countFunction*MFSD8*\
(NM_152778.2)ENSG00000164073/\
611,124/\
GO:0007040\
GO:0055085Major facilitator superfamily domain-containing 8, *CLN7*4q28.2/\
13 ExonsTransmembrane ubiquitous protein consists of major facilitator superfamily and transporter domains*AFF2*\
(NM_002025.3)ENSG00000155966/\
300,806/\
GO:0002151*AF4*/*FMR2* family member 2,\
fragile XE mental retardation syndrome protein,\
fragile X mental retardation 2 protein,\
protein FMR-2,\
*FMR2P*,\
*FMR2*,\
*OX19*, fragile X mental retardation 2, *AF4*/*FMR2* family member 2Xq28/\
22 ExonsG-quadruplex RNA binding, RNA splicing*OMIM* Online Mendelian Inheritance in ManRNA Ribonucleic acidTable 7Common reported mutations of *AFF2* and *MFSD8* genes, related signs and symptoms and disordersGeneCommon reported mutationsSigns and symptomsRelated disorders*MFSD8*\
(NM_152778.2)Missense and nonsense mutation, splice site mutation, frameshift, deletionSeizures or motor impairment, mental regression, myoclonus seizure, speech impairment, loss of motor function and quadriplegia, early onset loss of vision, sleep disorders, loss of cognitive functionCeroid lipofuscinosis, neuronal, 7*AFF2*\
(NM_002025.3)Triple expansion of GCC to \> 200 in comparison with 6--25 normal copy number of GCCMild-to-moderate mental retardation, learning disabilities, communication problems, attention loss, hyperactivity, autistic behaviors, metabolic and homeostatic abnormalitiesFragile XE syndrome,\
X-linked mental retardation associated with fragile site FRAXE,\
FRAXE intellectual disability*FRAXE* fragile XE syndrome

*MFSD8* is located on chromosome 4q28.1-q28.2; it has 55,180 bp and 13 exons, encoding a 4562 bp transcript and a protein with 518 amino acids. Major facilitator superfamily domain-containing protein 8 which encoded by *MFSD8* is a transmembrane ubiquitous protein that consists of a major facilitator superfamily (MFS) and transporter domains \[[@CR27]\]. This protein locates into lysosomal membrane and acts as a multi-pass membrane protein using chemiosmotic ion gradients \[[@CR30]\]. Figure [5](#Fig5){ref-type="fig"} shows topological structure of MFSD8 wild type and mutant protein. The deletion found in this patient affects the exon 5 of this gene which is the region encoding transmembrane domain. According to IRANOME database (<http://www.iranome.ir>/), the mean allele frequency of this variant is unknown.Fig. 5Front view and surface of MFSD8 protein. **a** Normal; **b** mutant. Structural topology has been changed in mutant form. Adapted from Yet Another Scientific Artificial Reality Application (YASARA)

Based on the NCL mutation database held at the University College London, at the time of writing this manuscript, there were 38 reported mutations in *MFSD8* gene in different populations \[[@CR9]\]. The most common mutations are missense and nonsense mutations; however, other types of mutations such as splice site, single bp deletion, frameshift, and one case of 17 bp deletion are also reported \[[@CR28]\].

Rare pathogenic variants in the AFF2 gene have been identified in patients with autism and attention deficit hyperactivity disorders as well as with X-linked intellectual disability and developmental and speech delay \[[@CR32], [@CR32]\]. In addition, this gene has been associated with syndromic autism, where a subpopulation of individuals with a given syndrome develops autism. A rare pathogenic variant in the *AFF2* gene has been identified in patients with fragile X syndrome \[[@CR32]\]. Mondal *et al.* suggested that rare variants in *AFF2* may be the cause for previously unrecognized autism spectrum disorder (ASD) susceptibility locus and may help to explain some of the male excess of ASD \[[@CR33]\]. The other related phenotypes to *AFF2* gene are abnormality of metabolism/homeostasis \[[@CR34]\], aggressive behavior \[[@CR35]\], epicanthic fold, and delayed speech and development of language \[[@CR36]\].

*AFF2* is a protein coding gene and member of the *AF4*\\*FMR2* gene family which is located on chromosome Xq28. This ribonucleic acid (RNA)-binding protein is implicated in the splicing process. The trinucleotide repeat expansion of CCG at 5′ untranslated region (UTR) of *AFF2* causes fragile XE syndrome (FRAXE) \[[@CR37]\]. More details of this gene are included in Tables [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"}. Although the hemizygous variant found in the affected male of this family segregates in the tested samples, based on the clinical symptoms of the affected male, this variant cannot explain the hallmark and pathognomonic characteristics observed in the affected male. So, based on the clinical findings, correlation of the *AFF2* variant with the disease in this family is very unlikely. Tables [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"} summarize the expected and observed phenotypic symptoms.

Conclusions {#Sec4}
===========

Sequencing analysis in this family has shown that the index is homozygous for 15 bp in-frame deletion, his uncle has normal homozygous, and his parents are heterozygous (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6Deoxyribonucleic acid sequence of mutated region. Normal homozygous uncle and heterozygous parents and homozygous patient for in-frame 15 base pairs deletion. *bp* base pairs

This pattern of mutation inheritance and the signs and symptoms observed in the affected male of this family are compatible with what is described in the literature for NCL type 7 and, therefore, suggest that the *MFSD8* deletion found in this study is most probably the cause of disease in this family.

AR

:   Autosomal recessive

ASD

:   Autism spectrum disorder

bp

:   Base pair

CCS

:   Consensus Coding Sequences

CLNs or NCLs

:   Neuronal ceroid lipofuscinoses

EEG

:   Electroencephalogram

FRAXE

:   Fragile XE syndrome

GC-MS

:   Gas chromatography--mass spectrometry

INCL

:   Infantile neuronal ceroid lipofuscinosis

JNCL

:   Juvenile neuronal ceroid lipofuscinosis

LINCL

:   Late infantile neuronal ceroid lipofuscinosis

MAF

:   Minor allele frequency

Mb

:   Mega base pairs

MFS

:   Major facilitator superfamily

NCLs or CLNs

:   Neuronal ceroid lipofuscinoses

*PPT*

:   Palmitoyl-protein thioesterase

TPP1

:   Tripeptidyl-peptidase 1

UTR

:   Untranslated region

WES

:   Whole exome sequencing

The Authors would like to give special thanks to the involved family who tightly collaborated with this report.

We are also grateful to Dr Ahmad Reza Salehi and Mr Ehsan Razmara for their assistance and valuable comments.

Availability of data and materials {#FPar1}
==================================

Results of genetic analysis are included in this report.

MG conducted the experiments. MG and AHB analysed the data. AHB contributed reagents/materials/analysis tools. MG and AHB wrote the paper. MG and AHB read and approved the final manuscript.

Ethics approval and consent to participate {#FPar2}
==========================================

The involved family was informed about the benefits and consequence of genetics testing and a written consent letter was also obtained for their participation.

Consent for publication {#FPar3}
=======================

Written informed consent was obtained from the patient's legal guardian(s) for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests {#FPar4}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar5}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
